

Press release

Hørsholm  
19 August 2015

## **ALK to present at the Morgan Stanley Global Healthcare Conference in New York**

Page 1/1

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that the Company will present at the Morgan Stanley Global Healthcare Conference in New York. Flemming Pedersen, CFO & EVP, will provide an overview of the Company and its key programmes on Thursday, 17 September at 3.30 PM Eastern Time.

### **ALK-Abelló A/S**

#### **For further information please contact:**

##### *Investor Relations:*

Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525  
Janet Dally, tel. +1 609-466-0466

##### *Press:*

Jeppe Ilkjær, tel. +45 7877 4532, mobile + 453050 2014

#### **About ALK**

*ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is a world leader in allergy immunotherapy – a treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with MSD (known as Merck (NYSE: MRK) in the USA and Canada), Torii, Abbott and bioCSL to commercialise sublingual allergy immunotherapy tablets in North America, Japan, Russia, Australia and New Zealand, respectively. The company is headquartered in Hørsholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at [www.alk.net](http://www.alk.net).*